DocDollars

Avadel Cns Pharmaceuticals, LLC

MO · United States · Reporting entity ID 100000786824

Total reported 2019–2025
$6.24M
#635 of 2,960 reporting companies — 0% of all reported industry payments
$3.55M in general payments across 22,971 records, plus $2.69M in research funding across 52 records.

How it breaks down

General payments $3,554,976
Research funding $2,689,983

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Avadel Cns Pharmaceuticals, LLC reported $6.24M to US doctors and teaching hospitals from 2019 to 2025, ranking #635 of 2,960 reporting companies. 43% of that was research funding and 57% general payments such as consulting, speaking, food and travel. 22,971 general payment records and 52 research records were filed.

Common questions about Avadel Cns Pharmaceuticals, LLC

How much has Avadel Cns Pharmaceuticals, LLC paid US doctors?

Avadel Cns Pharmaceuticals, LLC reported $6,244,959 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $3,554,976 in general payments, $2,689,983 in research funding.

How does Avadel Cns Pharmaceuticals, LLC rank among drug and device companies?

It ranks #635 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Avadel Cns Pharmaceuticals, LLC mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.